Q-omics provides the consensus-scored DCP1B profile across patient tissues and cancer cell-line models. DCP1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, DCP1B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DCP1B RNA expression shows 19,010 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, KIRC, and KIRP as cancer lineages where DCP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCP1B survival associations across molecular data types. DCP1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCP1B RNA expression–survival associations across cancer types. High DCP1B expression shows unfavorable associations in LGG, but favorable associations in SCLC, READ, BRCA, PRAD and UCEC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for DCP1B RNA expression.
This table summarizes DCP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCP1B shows lower tumor expression in UCEC and BLCA and higher tumor expression in KIRC, LIHC, KIRP and CHOL. The KIRC box plot shows higher DCP1B RNA expression in tumor versus normal tissue (log2 FC = +0.431, t-test p < 0.001).
This table shows molecular features associated with DCP1B in patient tissues and cancer cell lines. In patient samples, DCP1B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DCP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
